C-Path Expands Partnership with European Joint Programme on Rare Diseases

The independent global nonprofit Critical Path Institute and the European Joint Programme on Rare Diseases said they will collaborate to advance technologies and methodologies that are fit for regulatory purposes to further global rare disease research and drug development.

Photo: C-Path Chief Science Officer Klaus Romero

Both organizations will support the creation of an interoperable global data ecosystem for rare disease to expedite effective development of new therapies. The organizations said the partnership will benefit patients, regulators, advocacy stakeholders, researchers, and industry.

The European Joint Programme on Rare Diseases is an initiative that has received funding from the European Union’s Horizon 2020 research and innovation program.

The two organizations said they have established a collaboration using a shared data model to demonstrate that key datasets from both efforts can be queried simultaneously. Building on the experience from the past year, both organizations will support the creation of an interoperable global data ecosystem for rare disease to expedite effective development of new therapies.

“Collaboration is a foundational principle of success to address unmet needs in medical product development in rare diseases,” said C-Path Chief Science Officer Klaus Romero, “As novel approaches are vital to address these unmet needs, our partnership with EJP RD will expand our global capabilities in collaborating for methodologies and technologies to accelerate research with tangible impact for individuals and their families living with rare disease.”

Author: Rare Daily Staff